Combination Therapies
1 Documented Synergies
Several treatment combinations show evidence of synergistic benefit:
- H1 + H2 dual antihistamine blockade: Concurrent cetirizine/loratadine (H1) with famotidine/cimetidine (H2) for MCAS management—dual blockade more effective than either alone
- Cimetidine + valacyclovir: Cimetidine inhibits renal clearance of acyclovir (the active metabolite of valacyclovir), significantly increasing systemic antiviral concentrations (Stuijt et al. 2026). This pharmacokinetic synergy enables lower antiviral doses with equivalent efficacy, reducing energy cost
- Mitochondrial support stack: CoQ10 + NADH + D-ribose target complementary points in ATP production: electron transport (CoQ10), electron donation (NADH), and ATP backbone synthesis (D-ribose). The Castro-Marrero protocol (NADH 20 mg + CoQ10 200 mg) has the strongest RCT evidence (Castro-Marrero et al. 2021)
- LDN + PEA: Complementary anti-neuroinflammatory mechanisms—LDN via TLR4/microglia and PEA via PPAR-\(\alpha\)/mast cells—potentially providing broader neuroinflammatory coverage than either alone
2 Interaction Risks
- Serotonin syndrome risk: 5-HTP + SSRIs/SNRIs + trazodone—never combine serotonergic agents without physician supervision. Serotonin syndrome is a potentially fatal energy crisis
- CYP450 stacking: Cimetidine (CYP inhibitor) + multiple CYP-metabolized drugs (aripiprazole, SSRIs, beta-blockers)—inhibited clearance leads to drug accumulation. Review all drug interactions when cimetidine is part of the regimen
- Bleeding risk: Omega-3 + Ginkgo + CoQ10 + anticoagulants—cumulative antiplatelet effects. Monitor INR if combining multiple agents with anticoagulant properties
- Hypoglycemia: D-ribose + alpha-lipoic acid + fasting—both lower blood glucose. Take with food; monitor blood glucose in diabetic patients
3 Documented Synergies
4 Interaction Risks
- Serotonin syndrome risk: 5-HTP + SSRIs/SNRIs + trazodone—never combine serotonergic agents without physician supervision. Serotonin syndrome is a potentially fatal energy crisis
- CYP450 stacking: Cimetidine (CYP inhibitor) + multiple CYP-metabolized drugs (aripiprazole, SSRIs, beta-blockers)—inhibited clearance leads to drug accumulation. Review all drug interactions when cimetidine is part of the regimen
- Bleeding risk: Omega-3 + Ginkgo + CoQ10 + anticoagulants—cumulative antiplatelet effects. Monitor INR if combining multiple agents with anticoagulant properties
- Hypoglycemia: D-ribose + alpha-lipoic acid + fasting—both lower blood glucose. Take with food; monitor blood glucose in diabetic patients
Certainty: 0.35. Periostin (POSTN) is a matricellular protein critical for collagen crosslinking and tissue remodeling. It is upregulated by mechanical stress and downregulated by chronic inflammation. ME/CFS may involve periostin deficiency or dysregulation, impairing connective tissue repair. Recombinant periostin or periostin-inducing therapies (TGF-beta modulators) could restore ECM integrity. (Novel connection supported by basic science; periostin mutations cause connective tissue disorders; periostin deficiency causes ligament laxity; no direct ME/CFS data.)
Mechanistic Rationale. Periostin acts as a bridge between cells and the extracellular matrix, facilitating collagen fibril organization and crosslinking. It stabilizes collagen networks in tendons, ligaments, and bone, and is essential for proper connective tissue remodeling. In ME/CFS, chronic inflammation may downregulate periostin production while mechanical stress from hypermobility requires increased periostin for tissue repair. This creates a vicious cycle: inflammation reduces periostin → impaired collagen crosslinking → tissue weakness → increased mechanical stress → further inflammation. The fact that periostin mutations cause connective tissue disorders in humans provides direct evidence of its critical role in connective tissue integrity.
Testable Predictions.
- ME/CFS patients (especially hypermobile subset) will show reduced serum periostin levels compared to healthy controls
- Periostin levels will correlate with ligament laxity scores and POTS severity
- Recombinant periostin supplementation will improve collagen crosslinking markers (hydroxyproline, hydroxylysine)
- TGF-beta modulators that increase periostin expression will improve connective tissue symptoms in periostin-deficient patients
Clinical Implications. If validated, this represents a targeted biological approach to connective tissue pathology. Recombinant periostin could directly address the molecular basis of connective tissue weakness in ME/CFS hypermobility. TGF-beta modulators offer an alternative approach to stimulate natural periostin production.
Safety Considerations. Recombinant periostin is a novel therapeutic with unknown long-term safety. Potential immunogenicity risk must be monitored. TGF-beta modulators require careful dosing as excessive TGF-beta can promote fibrosis. Initial studies should start with very low doses and monitor for adverse effects.
Limitations. High certainty ceiling due to lack of direct ME/CFS data; periostin may have complex roles beyond simple collagen support; recombinant protein therapies are expensive; individual variation in periostin metabolism may affect response; timing and dosing protocols not established.
Treatment Implications. Pilot trial of recombinant periostin in ME/CFS hypermobile patients with documented periostin deficiency. Alternative approach using TGF-beta modulators like low-dose losartan (ARB that reduces pathological TGF-beta signaling while potentially improving physiological ECM production) in periostin-deficient patients.
5 Sequencing Considerations
- Serotonin syndrome risk: 5-HTP + SSRIs/SNRIs + trazodone—never combine serotonergic agents without physician supervision. Serotonin syndrome is a potentially fatal energy crisis
- CYP450 stacking: Cimetidine (CYP inhibitor) + multiple CYP-metabolized drugs (aripiprazole, SSRIs, beta-blockers)—inhibited clearance leads to drug accumulation. Review all drug interactions when cimetidine is part of the regimen
- Bleeding risk: Omega-3 + Ginkgo + CoQ10 + anticoagulants—cumulative antiplatelet effects. Monitor INR if combining multiple agents with anticoagulant properties
- Hypoglycemia: D-ribose + alpha-lipoic acid + fasting—both lower blood glucose. Take with food; monitor blood glucose in diabetic patients